ABCB1 and cancer: Furthermore, our study provides the possible scenario in which the cancer cells might develop resistance to ARS-1620 via ABCB1 overexpression, and the possible solution for this scenario is the combination therapy of ARS-1620 with an ABCB1 inhibitor.